









Atlas Genet Cytogenet Oncol Haematol. 2006;10(1)  3 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
JAK2 (janus kinase 2) 
Sabine Strehl 
Children's Cancer Research Institute, Kinderspitalgasse 6, A-1090 Vienna, Austria 
Published in Atlas Database: September 2005 
Online updated version: http://AtlasGeneticsOncology.org/Genes/JAK98.html  
DOI: 10.4267/2042/38263 
This article is an update of: Huret JL. JAK2 (janus kinase 2). Atlas Genet Cytogenet Oncol Haematol.1998;2(1):14. 
 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 







JAK2 (9p24) - Courtesy Mariano Rocchi, Resources for 
Molecular Cytogenetics.  
DNA/RNA 
Description 
25 exons spanning roughly 140 kb of genomic DNA; 
5402 bp pre-mRNA; 6 different transcripts, putatively 
encoding 4 different protein isoforms. 
Protein 
Description 
1132 amino acids; 130,7 kDa; JAK2 contains a central 
Src homology 2 (SH2) domain, and two C-terminal 
domains: a tyrosine kinase domain JH1 (also termed 
PTK or TyrKc domain), and a tyrosine kinase-like 




Intracellular, possibly membrane associated. 
Function 
Protein tyrosine kinase of the non-receptor type that 
associates with the intracellular domains of cytokine 
receptors; JAK2 is the predominant JAK kinase 
activated in response to several growth factors and
cytokines such as IL-3, GM-CSF and erythropoietin; i  
has been found to be constitutively associated withthe 
prolactin receptor and is required for responses to 
gamma interferon. 
Homology 
JAK2 belongs to the janus kinase subfamily; so far fou
mammalian JAKs have been identified (JAK1, JAK2, 
JAK3, and TYK2); human JAK2 is >90% identical to 
the mouse and the rat JAK2 homologs. 
Mutations 
Somatic 
A high proportion (>50%) of patients with 
myeloproliferative disorders (MPD; (polycythemia 
vera, essential thrombocythemia, idiopathic 
myelofibrosis - see below) carry a dominant gain-of-
function V617F mutation in the JH2 kinase-like 
domain of JAK2. This mutation leads to deregulation 
of the kinase activity, and thus to constitutive tyrosine 
phosphorylation activity. The incidence of the V617F 
mutation in different studies ranges from 65-97% in 
polycythemia vera, from 41-57% in patients with 
essential thrombocythemia, and from 23-95% in 
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patients with idiopathic myelofibrosis. In MPD the 
mutation is heterozygous in most patients and 
homozygous only in a minor subset. Mitotic 
recombination probably causes both 9p LOH and the 
transition from heterozygosity to homozygosity. The 
same mutation was also found in roughly 20% of Ph-
negative atypical CML, in more than 10% of CMML, 
in about 15% of patients with megakaryocytic AML 
(AML M7), and 1/5 patients with juvenile 
myelomonocytic leukemia (JMML). The V617F 
mutation seems to occur exclusively in hematopietic 
malignancies of the myeloid lineage. 
Implicated in 
t(8;9)(p21-22;p24)/acute leukaemias → 
PCM1-JAK2 
Disease 
Myeloid and lymphoid malignancies; predominantly 
atypical CML, but also found in chronic eosinophilic 
leukemia (CEL), (secondary) AML, and MDS/MPD; 
thirteen cases described to date, all male, except for one 
childhood female case with erythroid leukemia with 
multiple bone tumors. 
Prognosis 
Highly variable; allogeneic stem cell transplantation 
may be the only curative treatment. 
Hybrid/Mutated Gene 
5’ PCM1 - 3’ JAK2; only in some cases the reciprocal 
5’ JAK2 - 3’ PCM1 is present. 
Abnormal Protein 
Almost the entire PCM1 protein containing multiple 
coiled-coil domains is fused to the tyrosine kinase C-
terminal domains (JH2 and JH1) of JAK2. 
Oncogenesis 
Dimerization or oligomerization of the PCM1-JAK2 
chimera through one or more of the coiled-coil motifs 
of PCM1 probably results in the constitutive activation 
of the tyrosine kinase domain of JAK2. 
t(9;12)(p24;p13) acute leukaemias → 
JAK2/ETV6 
Disease 
Myeloid and lymphoid leukemias; only three cases 
described to date; one case each: childhood T-ALL, pre 











5' ETV6 - 3' JAK2 
Abnormal Protein 
In the atypical CML the N-terminal HLH of ETV6 is 
fused to the tyrosine kinase C-terminal domains (JH2 
and JH1) of JAK2; in the B-ALL the same ETV6 
domain is fused to part of the JH2 and the complete 
JH1 domain, and in the T-ALL case to the JH1 domain. 
Oncogenesis 
It may be speculated that the HLH domain of ETV6 
provides a dimerization interface to the kinase domain 
of JAK2, which activates JAK2; ETV6-JAK2 
transgenic mice - generated using a T-ALL specific 




Atypical CML; only one case described to date. 
Hybrid/Mutated Gene 
5’ BCR - 3’ JAK2; absence of the reciprocal 5’ JAK2 - 
3’ BCR. 
Abnormal Protein 
The N-terminal coiled-coil domain of BCR is fused to 
the JH1 tyrosine kinase C-terminal domain of JAK2. 
Oncogenesis 
Constitutive activation of the tyrosine kinase domain of 
JAK2 mediated through oligomerization through the 





Note: the V617F mutation in JAK2 could form the 
basis for a new molecular classification of 
myeloproliferative disorders. 
Disease 
Chronic myeloproliferative syndromes. 
Oncogenesis 
A significant percentage of patients with 
myeloproliferative disorders carries a dominant gain of 
function V617F mutation in JAK2; this mutation seems 
to lead to deregulation of the kinase activity of JAK2, 
and thus to constitutive tyrosine phosphorylation 
activity, providing hematopoietic cells with a 
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